Replimune REPL 深 滬
等待開盤 07-23 09:30:00 美东时间
10.75
-0.250
-2.27%
華盛通- 最 高11.235
- 今 開10.97
- 成交量 162.60万股
- 最 低 10.685
- 昨 收 11.00
- 總市值 9.02亿
- 52周最高 12.50
- 市盈率 靜 --
- 換手率 1.94%
- 52周最低 1.50
- 委 比 82.59%
- 總股本 8394.52万
- 歷史最高 54.79
- 量 比 0.47
- 振 幅 5.00%
- 歷史最低 1.50
- 每 手 1
- 風險率 2.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多期权扫描 | SpaceX现巨量末日Put单！豪赌跌穿135美元IPO发行价；Figma多张Call单涨逾900%
SpaceX现巨量末日Put单！豪赌跌穿135美元IPO发行价；Figma多张Call单涨逾900%；苹果股价逆势创新高，期权放量至195万张>>
07-14 19:10
9 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away fro...
07-10 01:35
Four stock-moving events to watch as FDA revives AdComs
The Advisory Committee meetings, a key regulatory step in U.S. drug and MedTech approvals, are making a comeback as the Food and Drug Administration seeks to revisit several controversial decisions ma...
07-02 01:51
美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元
今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元
07-01 10:40
分析师解读医疗企业 Replimune Group（REPL）、Abivax SA 担保ADR（ABVX）及Larimar Therapeutics（LRMR）
3位医疗领域五星分析师近期分别对3只美股医疗保健个股给出看涨评级，相关核心信息如下： Replimune Group（REPL）：摩根大通将其评级上调至买入...
06-30 22:02
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wedbush raised the price target for Replimune Group Inc (NASDAQ:REPL) from $6 to $9. Wedbush analyst Robert Dr...
06-30 21:04
Wedbush Maintains Neutral on Replimune Group, Raises Price Target to $9
Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ:REPL) with a Neutral and raises the price target from $6 to $9.
06-30 20:51
财报速睇 | Replimune 2026财年年度营收0.00亿美元，同比增长0.0%；归母净利润亏损3.14亿美元，同比亏损扩大26.9%
华盛资讯6月29日讯，Replimune公布2026财年年度业绩，公司年度营收0.00亿美元，同比增长0.0%，归母净利润亏损3.14亿美元，同比亏损扩大26.9%。
06-29 23:18
财报速睇 | Replimune 2026财年年度营收0.00亿美元，同比增长0.0%；归母净利润亏损3.14亿美元，同比亏损扩大27.0%
华盛资讯6月29日讯，Replimune公布2026财年年度业绩，公司年度营收0.00亿美元，同比增长0.0%，归母净利润亏损3.14亿美元，同比亏损扩大27.0%。
06-29 23:02
Replimune Group Q4 EPS $(0.76) Misses $(0.71) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.71) by 7.04 percent. This is a 7.32 percent increase over losses of $(0.82) per share from the same period last year.
06-29 20:52
